We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+57.27%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.67B
AUM Growth
+$471M
(+39%)
Cap. Flow
-$59.6M
Cap. Flow
% of AUM
-3.58%
Top 10 Holdings %
Top 10 Hldgs %
75.81%
Holding
42
New
5
Increased
4
Reduced
20
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$21.5M |
| 2 |
Gossamer Bio
GOSS
|
+$2.57M |
| 3 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$2.06M |
| 4 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$1.96M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$1.71M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$21M |
| 2 |
STAAR Surgical
STAA
|
+$18.7M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$13.7M |
| 4 |
United Therapeutics
UTHR
|
+$12.4M |
| 5 |
WMGI
Wright Medical Group Inc
WMGI
|
+$6.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMMU
1
DELISTED
Immunomedics Inc
IMMU
| $184M | 11.03% |
5,182,983
-107,763
| -2% | -$3.15M |
|
|
2
STAAR Surgical
STAA
$1.25B
| $174M | 10.42% |
2,821,154
-457,369
| -14% | -$18.7M |
|
|
3
BioMarin Pharmaceuticals
BMRN
$13.3B
| $173M | 10.41% |
1,405,950
-138,213
| -9% | -$13.7M |
|
4
Insmed
INSM
$29.4B
| $165M | 9.93% |
6,002,289
-53,334
| -0.9% | -$1.26M |
|
|
ABMD
5
DELISTED
Abiomed Inc
ABMD
| $119M | 7.14% |
492,333
-10,412
| -2% | -$2.09M |
|
|
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
| $111M | 6.64% |
7,334,714
-112,904
| -2% | -$1.38M |
|
|
7
United Therapeutics
UTHR
$22.7B
| $92.7M | 5.57% |
766,406
-110,169
| -13% | -$12.4M |
|
|
EPZM
8
DELISTED
Epizyme, Inc
EPZM
| $88.5M | 5.32% |
5,513,676
-38,127
| -0.7% | -$666K |
|
9
Karyopharm Therapeutics
KPTI
$44.4M
| $79.9M | 4.8% |
281,297
-5,363
| -2% | -$1.59M |
|
10
Acadia Pharmaceuticals
ACAD
$5.06B
| $75.9M | 4.55% |
1,564,900
-66,624
| -4% | -$3.2M |
|
|
AIMT
11
DELISTED
Aimmune Therapeutics
AIMT
| $55.4M | 3.33% |
3,318,212
+22,500
| +0.7% | +$382K |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
| $49.9M | 3% |
444,629
-197,862
| -31% | -$21M |
|
|
MNTA
13
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $49.2M | 2.96% |
1,479,524
-48,432
| -3% | -$1.54M |
|
14
Vanda Pharmaceuticals
VNDA
$304M
| $47.1M | 2.83% |
4,116,548
-18,298
| -0.4% | -$207K |
|
|
RVNC
15
DELISTED
Revance Therapeutics, Inc.
RVNC
| $41.6M | 2.5% |
1,704,372
+1,088,667
| +177% | +$21.5M |
|
|
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
| $29.4M | 1.77% |
4,361,411
-274,378
| -6% | -$2.08M |
|
|
SAGE
17
DELISTED
Sage Therapeutics
SAGE
| $23.9M | 1.44% |
575,200
-11,474
| -2% | -$416K |
|
|
AMAG
18
DELISTED
AMAG Pharmaceuticals
AMAG
| $22.6M | 1.36% |
2,959,587
-43,161
| -1% | -$330K |
|
19
Align Technology
ALGN
$12.5B
| $18.5M | 1.11% |
67,505
-8,700
| -11% | -$1.96M |
|
20
Puma Biotechnology
PBYI
$449M
| $14M | 0.84% |
1,343,897
-52,266
| -4% | -$541K |
|
|
DRNA
21
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $8.43M | 0.51% |
331,813
| – | – |
|
22
Prothena Corp
PRTA
$468M
| $8.06M | 0.48% |
771,065
-4,231
| -0.5% | -$47K |
|
23
Rigel Pharmaceuticals
RIGL
$778M
| $6.48M | 0.39% |
354,255
| – | – |
|
|
KLDO
24
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $5.84M | 0.35% |
786,400
-1,599
| -0.2% | -$10.7K |
|
25
Cytokinetics
CYTK
$10.8B
| $2.92M | 0.18% |
123,686
| – | – |
|
Similar funds
RRA
AG
BL
CG
SCM
GAMA
PIM
ACA
Palo Alto Investors's Q2 2020 Portfolio in Review
As of Q2 2020, Palo Alto Investors held 42 positions worth $1.67B, up 39% from $1.19B the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Palo Alto Investors withdrew a net $59.6M in Q2 2020, closing 1 position and reducing 20 holdings. Its most notable exit was Wright Medical Group Inc, an estimated $6.96M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 88% a quarter earlier.
Against the trend, Palo Alto Investors opened a new position in Gossamer Bio worth $2.65M.
- Palo Alto Investors's largest Q2 2020 buy was Gossamer Bio: 204,214 shares worth $2.65M.
- Palo Alto Investors added most to Revance Therapeutics, Inc. in Q2 2020, an estimated $21.5M increase.
- Palo Alto Investors's biggest Q2 2020 reduction was Alexion Pharmaceuticals, cutting an estimated $21M.
- Palo Alto Investors fully exited Wright Medical Group Inc in Q2 2020, selling an estimated $6.96M.
- Palo Alto Investors's ten largest holdings make up 76% of its $1.67B portfolio in Q2 2020.
- Palo Alto Investors opened 5 new positions and closed 1 in Q2 2020.
- Palo Alto Investors's portfolio value rose 39% quarter-over-quarter to $1.67B.
Based on Palo Alto Investors's 13F filing for Q2 2020, filed 14 Aug 2020.